RGD Reference Report - Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors: Huang, Chaolin  Wang, Yeming  Li, Xingwang  Ren, Lili  Zhao, Jianping  Hu, Yi  Zhang, Li  Fan, Guohui  Xu, Jiuyang  Gu, Xiaoying  Cheng, Zhenshun  Yu, Ting  Xia, Jiaan  Wei, Yuan  Wu, Wenjuan  Xie, Xuelei  Yin, Wen  Li, Hui  Liu, Min  Xiao, Yan  Gao, Hong  Guo, Li  Xie, Jungang  Wang, Guangfa  Jiang, Rongmeng  Gao, Zhancheng  Jin, Qi  Wang, Jianwei  Cao, Bin 
Citation: Huang C, etal., Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
RGD ID: 30309212
Pubmed: PMID:31986264   (View Abstract at PubMed)
PMCID: PMC7159299   (View Article at PubMed Central)
DOI: DOI:10.1016/S0140-6736(20)30183-5   (Journal Full-text)


BACKGROUND: A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients.
METHODS: All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not.
FINDINGS: By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0-58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0-13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα.
INTERPRETATION: The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies.
FUNDING: Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
COVID-19 severityIEP 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOCCL2 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOCCL3 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOCCL4 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOCSF2 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOCSF3 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOCXCL10 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOFGF2 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOIFNG (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOIL10 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOIL13 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOIL17A (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOIL1B (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOIL1R1 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOIL2 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOIL4 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOIL6 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOIL7 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOIL9 (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOPDGFB (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOTNF (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 
COVID-19 severityISOVEGFA (Homo sapiens)30309212; 30309212protein:increased expression:plasma (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Ccl2  (C-C motif chemokine ligand 2)
Ccl3  (C-C motif chemokine ligand 3)
Ccl4  (C-C motif chemokine ligand 4)
Csf2  (colony stimulating factor 2)
Csf3  (colony stimulating factor 3)
Cxcl10  (C-X-C motif chemokine ligand 10)
Fgf2  (fibroblast growth factor 2)
Ifng  (interferon gamma)
Il10  (interleukin 10)
Il13  (interleukin 13)
Il17a  (interleukin 17A)
Il1b  (interleukin 1 beta)
Il1r1  (interleukin 1 receptor type 1)
Il2  (interleukin 2)
Il4  (interleukin 4)
Il6  (interleukin 6)
Il7  (interleukin 7)
Il9  (interleukin 9)
Pdgfb  (platelet derived growth factor subunit B)
Tnf  (tumor necrosis factor)
Vegfa  (vascular endothelial growth factor A)

Genes (Mus musculus)
Ccl2  (C-C motif chemokine ligand 2)
Ccl3  (C-C motif chemokine ligand 3)
Ccl4  (C-C motif chemokine ligand 4)
Csf2  (colony stimulating factor 2 (granulocyte-macrophage))
Csf3  (colony stimulating factor 3 (granulocyte))
Cxcl10  (C-X-C motif chemokine ligand 10)
Fgf2  (fibroblast growth factor 2)
Ifng  (interferon gamma)
Il10  (interleukin 10)
Il13  (interleukin 13)
Il17a  (interleukin 17A)
Il1b  (interleukin 1 beta)
Il1r1  (interleukin 1 receptor, type I)
Il2  (interleukin 2)
Il4  (interleukin 4)
Il6  (interleukin 6)
Il7  (interleukin 7)
Il9  (interleukin 9)
Pdgfb  (platelet derived growth factor, B polypeptide)
Tnf  (tumor necrosis factor)
Vegfa  (vascular endothelial growth factor A)

Genes (Homo sapiens)
CCL2  (C-C motif chemokine ligand 2)
CCL3  (C-C motif chemokine ligand 3)
CCL4  (C-C motif chemokine ligand 4)
CSF2  (colony stimulating factor 2)
CSF3  (colony stimulating factor 3)
CXCL10  (C-X-C motif chemokine ligand 10)
CXCL8  (C-X-C motif chemokine ligand 8)
FGF2  (fibroblast growth factor 2)
IFNG  (interferon gamma)
IL10  (interleukin 10)
IL13  (interleukin 13)
IL17A  (interleukin 17A)
IL1B  (interleukin 1 beta)
IL1R1  (interleukin 1 receptor type 1)
IL2  (interleukin 2)
IL4  (interleukin 4)
IL6  (interleukin 6)
IL7  (interleukin 7)
IL9  (interleukin 9)
PDGFB  (platelet derived growth factor subunit B)
TNF  (tumor necrosis factor)
VEGFA  (vascular endothelial growth factor A)


Additional Information